00:00Eosinophile diseases and the evolution of the therapeutic approach of the monoclonal antibody
00:10Mepulizumab have been at the center of the symposium promoted by GSK, organized during the second day of the 25th National Congress of the Italian Society of Pneumology,
00:20entitled Pneumology, the future is now, which took place in Mico di Milano from November 16 to 18.
00:27The clinical trials with the use of Mepulizumab in patients with serious asthma
00:36have confirmed the effectiveness of the drug in the clear reduction since the first supply of reacutizations,
00:46on the control of symptoms and on the improvement.
00:49The real-life studies have confirmed not only the improvement since the initial phases,
01:02but also the maintenance of this gain in terms of quality of life and the clinical and biological parameters that have been analyzed.
01:12The future is to evaluate in a longer period of time the maintenance of the clinical remission.
01:21The data are encouraging in this sense, but also the clinical experience that anyone who works on the field knows that can keep
01:30and knows that can count on an effective drug like the antithelioquine 5 and Mepulizumab.
01:36Granulomatosis eosinophila with polyangiitis and GPA is a rare disease characterized by inflammation of the blood vessels
01:43of small and medium sizes, potentially risky for patients with serious asthma.
01:48The coincidence is between 2 and 7 cases per million inhabitants, while the prevalence is between 10 and 13 cases per million inhabitants.
01:56Thanks to Mepulizumab it is possible to reduce the reacutizations of the disease.
02:01In the maintenance of the disease and in the treatment of the relapses of the disease,
02:07since 2017 by the MIRRA study, we have the possibility of using a monoclonal antibody, Mepulizumab,
02:14and it allows to block the interleukin 5, which in turn is the most specific and main growth factor of eosinophils,
02:21which are the key driver cell of the pathogenesis of the vascular disease called GPA.
02:28Mepulizumab allows to reduce the amount of systemic steroids given to the patients,
02:38with consequent benefits on the side effects, which are really very broad,
02:43such as diabetes, the risk of infectious diseases, osteoporosis, hypertension, eye damage.
02:50Mepulizumab also allows to have an increase of the weeks in which the pathology is under control,
02:57that is, the time from the first relapse of the disease.
Comments